Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
251 hedge funds and large institutions have $7.66B invested in Sage Therapeutics in 2018 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 104 increasing their positions, 67 reducing their positions, and 28 closing their positions.
104% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 28
55% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 67
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
18% more call options, than puts
Call options by funds: $62.1M | Put options by funds: $52.6M
12% more funds holding
Funds holding: 224 → 251 (+27)
5% more capital invested
Capital invested by funds: $7.26B → $7.66B (+$395M)
3.43% less ownership
Funds ownership: 107.36% → 103.93% (-3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$143M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$107M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.7M |
| 4 |
BlackRock
New York
|
+$56M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$49.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$86.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$34.6M |
| 4 |
Barclays
London,
United Kingdom
|
-$33M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$32.9M |
SAGE Hedge Fund Activity: Q1 2018 in Review
251 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2018, worth a combined $7.66B — up 5.4% from $7.26B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new SAGE positions and 28 closed out — a net gain of 29 holders — while 104 added to existing stakes and 67 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $143M. The largest seller was TRV GP II, cutting an estimated $86.7M.
- 251 institutional investors held Sage Therapeutics (SAGE) as of Q1 2018, up from 224 in Q4 2017.
- Funds reported $7.66B of Sage Therapeutics stock for Q1 2018, up 5.4% quarter-over-quarter.
- 57 funds opened new Sage Therapeutics positions in Q1 2018 and 28 closed out, a net change of +29 holders.
- The largest Sage Therapeutics buyer in Q1 2018 was T. Rowe Price Associates, an estimated $143M added.
- The largest Sage Therapeutics seller in Q1 2018 was TRV GP II, an estimated $86.7M sold.
Based on aggregated 13F filings for Q1 2018.